LGC acquires Axolabs 


LGC acquires Axolabs and invests in GMP manufacturing capacity for therapeutic nucleic acids

London (3 April 2017) – LGC today announced that it has acquired Axolabs, a leading Contract
Research, Development and Manufacturing Organisation, specialising in the development of
therapeutic nucleic acids (TNAs).

LGC also announced a major investment at its Biosearch subsidiary in Petaluma, California, USA

to expand its GMP oligonucleotide manufacturing capacity to provide TNA synthesis to the 1kg
scale in support of early stage clinical trials.

The acquisition and investment in GMP capacity position LGC as a world leading solutions
provider for TNAs and strengthen its existing analytical and bioanalytical drug development
service offering. Customers will benefit from integrated analytical and manufacturing solutions
spanning lead discovery through to the clinic and beyond

Dr David Griffiths, Managing Director of LGC’s LMS division, said: “We are delighted to be

welcoming Axolabs to LGC. With more than 16 years’ experience in the therapeutic nucleic acid
market Axolabs enjoys a strong reputation for scientific excellence, quality and reliability –
attributes that match LGC’s. Axolabs’ in-depth know-how in the TNA drug development field
complements LGC’s capabilities in GMP oligo manufacture, CMC analytical and bioanalytical
services and we look forward to working together with the Axolabs team and its customers.”

Dr Hans-Peter Vornlocher, Managing Director Research of Axolabs, said: “It is clear that LGC
shares our passion for delivering the highest quality science and service for our customers. This
transition of ownership allows us to continue to invest in our team and facilities at Kulmbach.
Combining Axolabs’ pre-clinical expertise and LGC’s GMP manufacturing capabilities allows us
to support our clients further along the drug development pathway. Moreover, the access to
LGC’s leading science and international reach enables us offer a broader set of solutions for our
customers.” 

Based in Kulmbach, Southern Germany, Axolabs employs 60 people and delivers integrated
research solutions for TNAs, covering in-silico design, synthesis, analytics, bioanalytics, biology,
pharmacology and consulting services. Axolabs’ expertise spans a wide range of TNA
modalities including antisense oligos, siRNAs, immunostimulatory oligos, aptamers, microRNAs
and microRNA mimics, synthetic mRNAs and guide RNAs for CRISPR applications. Axolabs’
management team will remain with the business following the transaction.

Ends)

About LGC

LGC is an international life sciences measurement and testing company with leading positions in growing

markets. LGC provides a range of measurement products and services which underpin the safety, health and
security of the public, including reference materials and proficiency testing, genomics reagents and
instrumentation, and expert sample analysis and interpretation. LGC serves customers across a number of end
markets including Pharmaceuticals, Agricultural Biotechnology, Diagnostics, Food, Environment, Government
and Academia.

LGC’s headquarters are in London and the company employs over 2,600 people, operating out of 22 countries

worldwide. Its operations are extensively accredited to international quality standards such as ISO/IEC 17025,
ISO 13485, ISO 9001, GMP, GLP and ISO Guide 34. 

With a history dating back to 1842, LGC has been home to the UK Government Chemist for more than 100 years

and is the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement.
LGC was privatised in 1996 and is now owned by funds affiliated with KKR.

For more information, please visit www.lgcgroup.com 

About Axolabs

Axolabs is a leading Contract Research, Development and Manufacturing Organisation, focused on the discovery

and pre-clinical phases of drug development in the field of oligonucleotide therapeutic and other nucleic acid
medicines. The company was founded in 2000 as Ribopharma, a spin-out from the University of Bayreuth, as the
world’s first RNAi therapeutics company. It subsequently became part of Alnylam and then Roche and was the
subject of a management buy-out in late 2011. 

For more information, please visit www.axolabs.com

For more information

Guenaelle Holloway, LGC, Corporate Communications
+44 20 8943 7563
Guenaelle.holloway@lgcgroup.com